The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as their associated cancer stem cells, the company announced today.

“This patent provides intellectual property protection for one of our most interesting paclitaxel PDCs,” Cellectar Biosciences President and CEO Jim Caruso said in a statement.

According to a release, the patent provides intellectual property protection for CLR 1603 to the end of 2035.